Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | — |
The patient took two doses of Vivotif in a row instead of every other day; Case reference number US-BN-2025-001896 is a spontaneous case initially received from a pharmacist via Bavarian Nordic (reference number: CASE-000994) on 02-Dec-2025 and concerns an adult female patient of unknown age. The patient's medical history and concomitant medications details were not provided. On unspecified date, the patient took first dose of Vivotif (batch number: unknown) at an unknown dose, route and site of administration for an unknown indication. On unspecified date, in the next day, the patient took second dose of Vivotif (batch number: unknown) at an unknown dose, route and site of administration. As specified the patient took two doses in a row instead of every other day (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information was provided.; Reporter's Comments: An adult female patient of unknown age took two doses of Vivotif for an unknown indication in a row instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: An adult female patient of unknown age took two doses of Vivotif for an unknown indication in a row instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.